[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sana Biotechnology Inc (SANA)

Sana Biotechnology Inc (SANA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 961,172
  • Shares Outstanding, K 269,992
  • Annual Sales, $ 0 K
  • Annual Income, $ -244,170 K
  • EBIT $ -250 M
  • EBITDA $ -238 M
  • 60-Month Beta 2.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.81

Options Overview Details

View History
  • Implied Volatility 107.33% (-3.00%)
  • Historical Volatility 64.61%
  • IV Percentile 21%
  • IV Rank 26.25%
  • IV High 212.15% on 02/05/26
  • IV Low 70.03% on 01/27/26
  • Expected Move (DTE 3) 0.66 (20.34%)
  • Put/Call Vol Ratio 0.16
  • Today's Volume 288
  • Volume Avg (30-Day) 613
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 28,533
  • Open Int (30-Day) 28,586
  • Expected Range 2.60 to 3.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.14
  • Number of Estimates 4
  • High Estimate $-0.12
  • Low Estimate $-0.18
  • Prior Year $-0.16
  • Growth Rate Est. (year over year) +12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.05 +7.06%
on 04/29/26
4.08 -20.10%
on 04/14/26
+0.17 (+5.50%)
since 04/10/26
3-Month
2.66 +22.56%
on 03/30/26
4.45 -26.74%
on 02/25/26
-0.53 (-13.98%)
since 02/12/26
52-Week
1.60 +103.75%
on 05/15/25
6.55 -50.23%
on 10/15/25
+1.26 (+63.00%)
since 05/12/25

Most Recent Stories

More News
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs

SEATTLE, May 12, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the presentation of...

SANA : 3.26 (-8.43%)
Sana: Q1 Earnings Snapshot

Sana: Q1 Earnings Snapshot

SANA : 3.26 (-8.43%)
Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451 Continued progress toward starting SC451 Phase 1 trial later...

SANA : 3.26 (-8.43%)
Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference

SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast...

SANA : 3.26 (-8.43%)
Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting

SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that an abstract...

SANA : 3.26 (-8.43%)
Sana Biotechnology and Mayo Clinic Announce Strategic Collaboration Focused on Improving Care in Type 1 Diabetes and Accelerating Development of SC451

Sana and Mayo Clinic to collaborate across multiple areas with goal of accelerating development of and access to potentially curative therapies for patients with type 1 diabetes Initial efforts will...

SANA : 3.26 (-8.43%)
Sana Biotechnology Announces Continued Positive Clinical Results Through 14 Months from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Groundbreaking First-in-Human Study Demonstrates Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression 14-Month Follow-up Data Show Hypoimmune (HIP)-Modified...

SANA : 3.26 (-8.43%)
Sana: Q4 Earnings Snapshot

Sana: Q4 Earnings Snapshot

SANA : 3.26 (-8.43%)
Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Shared 12-month clinical results of ongoing UP421 type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression are safe and well-tolerated, evade...

SANA : 3.26 (-8.43%)
Sana Biotechnology to Present at March 2026 Investor Conferences

SEATTLE, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast...

SANA : 3.26 (-8.43%)

Business Summary

Sana Biotechnology Inc. is focused on creating and delivering engineered cells as medicines for patients. The company involved in repairing and controlling genes, replacing missing or damaged cells as well as making its therapies. Sana Biotechnology Inc. is based in SEATTLE.

See More

Key Turning Points

3rd Resistance Point 3.82
2nd Resistance Point 3.70
1st Resistance Point 3.48
Last Price 3.26
1st Support Level 3.14
2nd Support Level 3.02
3rd Support Level 2.80

See More

52-Week High 6.55
Fibonacci 61.8% 4.66
Fibonacci 50% 4.08
Fibonacci 38.2% 3.49
Last Price 3.26
52-Week Low 1.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.